Business
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine
About this update from Equillium, Inc.
[{"type":"text","content":"\nItolizumab continues to show clinically meaningful response in highly proteinuric subjects\n\n\nAt Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR)\n\n\nItolizumab demonstrated a favorable safety and tolerability profile\n\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study in lupus nephritis patients was presented at the annual meeting of the American Society of Nephrology (ASN). The data highlights that subjects had high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added to mycophenolate mofetil (MMF) and corticosteroids.\n\n\n“The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium. “We are encouraged that we continue to see clinically meaningful response rates, particularly in these highly proteinuric subjects. While the study is largely complete, we plan to deliver the full data package to Ono Pharmaceutical under the terms of our strategic partnership in early 2024.”\n\n\n“I’m excited that we saw both early and deep reductions in proteinuria,” said Dr. Maple Fung, chief medical officer at Equillium. “Physicians are looking for a treatment that can safely and rapidly reduce the levels of proteinuria in patients, as this is historically associated with improved long-term outcomes. The data from the EQUALISE study demonstrates that subjects had high complete and partial response rates and tolerated well the subcutaneous injections every two weeks; this is in the setting of tapering their systemic corticosteroids, maintaining stable kidney function, or eGFR, and increasing serum albumin while on study.”\n\n\nThe Type B portion of the EQUALISE study in patients with active proliferative LN (apLN) is evaluating the safety, tolerability and clinical activity of subcutaneous delivery of itolizumab. Patients must present with greater than 1 gram of proteinuria and have a recent kidney biopsy showing ISN/RPS class III or IV apLN to be eligible for the s...